02-07-02

Docket No. 300.1042US

Total Pages in this Submission

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

TO THE ASSISTANT COMMISSIONER FOR PATENTS **Box Patent Application**

Washington, D.C. 20231 Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled: METHOD FOR TREATING AMYLOID β PRECURSOR DISORDER and invented by: Lawrence FRIEDHOFF; Joseph BUXBAUM and Edward I. CULLEN f a CONTINUATION APPLICATION, check appropriate box and supply the requisite information: Continuation
Divisional Continuation-in-part (CIP) of prior application No.: ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: ______ Which is a: ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: AVhich is a: M Enclosed are: **Application Elements** Filing fee as calculated and transmitted as described below Specification having ______ pages and including the following: Descriptive Title of the Invention a. 🛛 Cross References to Related Applications (if applicable) b. 🛛 Statement Regarding Federally-sponsored Research/Development (if applicable) c. 🔲 Reference to Microfiche Appendix (if applicable) d. 🔲 Background of the Invention e. 🛛 Brief Summary of the Invention f. 🛛 Brief Description of the Drawings (if drawings filed) g. 🗀 **Detailed Description** h. 🛛 Claim(s) as Classified Below i. 🛛 Abstract of the Disclosure j. 🛛

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1042US

Total Pages in this Submission 83

Application Elements (Continued)

					Application Elements (Continued)	
	3.	X	Draw	ving(s) (when neces	ssary as prescribed by 35 USC 113)	
		a.	_	Formal	Number of Sheets	
		b.	X	Informal	Number of Sheets7	
	4.	×	Oath	n or Declaration	- Unavaguted	
		a	X	Newly executed (d	original or copy) Unexecuted	
		b	. 🗆	Copy from a prior	application (37 CFR 1.63(d)) (for continuation/divisional application only)	
		C	. 🗵	With Power of Att		
		d	i. 🗀	see 37 C.F.R. 1.6	63(d)(2) and 1.33(b).	
The first time of	ţ	5. 🗆	Th	corporation By Refe e entire disclosure ox 4b, is considere corporated by refere	erence (usable if Box 4b is checked) of the prior application, from which a copy of the oath or declaration is suppled as being part of the disclosure of the accompanying application and ence therein.	ied under is hereby
		6. [_ Co	omputer Program ir	n Microfiche (Appendix)	
I H Mare H H same H H Mare	ľ	7. (ן Nי	ucleotide and/or An	nino Acid Sequence Submission (if applicable, all must be included)	
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			a. 🗆			
1	į		b. [Computer Read	dable Copy (identical to computer copy)	
1			c. [] Statement Verit	fying Identical Paper and Computer Readable Copy	
١					Accompanying Application Parts	
		8.			(cover sheet & document(s))	
		9.		37 CFR 3.73(B) Sta	atement (when there is an assignee)	
		10.		English Translation	n Document (if applicable)	
		11.		Information Disclos	sure Statement/PTO-1449	
		12.		Preliminary Amend	dment	
		13.	×	Acknowledgment p	postcard	1
		14.	. ×	Certificate of Maili	ing	
				☐ First Class	Express Mail (Specify Label No.): EL 914 492 358 US	01ULRG/REV05
					Page 2 of 4	<u> </u>

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

C) 17.

4

 Docket No. 300.1042US

Total Pages in this Submission 8.3

		Accompanying Application Parts (Continued)
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.	×	Additional Enclosures (please identify below): Letter re: Priority

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1042US

Total Pages in this Submission

83

	CLAIMS AS FILED					
For	#Filed	#Allowed	#Extra		Rate	Fee
Ul	40	- 20 =	20	х	\$18.00	\$360.00
Total Claims III Indep. Claims	6	- 3 =	3	х	\$84.00	\$252.00
						\$0.00
pasic EEE						\$740.00
					\$0.00	
OTHER FEE (specify purpose)					\$1,352.00	

A check in the amount of

\$1,352.00

to cover the filing fee is enclosed.

▼ The Commissioner is hereby authorized to charge and credit Deposit Account No.

50-0552

as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of

as filing fee.

☑ Credit any overpayment.

☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.

☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,

pursuant to 37 C.F.R. 1.311(b).

Robert J. Paradisø, Reg. No. 41,240 Davidson, Davidson & Kappel, LLC

485 Seventh Avenue, 14th floor New York, New York 10018

212-736-1940

Dated: February 5, 2002



PATENT TRADEMARK OFFICE

CERTIFICATE OF MA	AILANG BY "EXPRESS M	MAIL" (37 CFR 1.16)	Docket No. 300.1042US		
Serial No. Not yet known	Filing Date Herewith	Examiner Not yet known	Group Art Unit Not yet known		
vention: METHOD FOR	TREATING AMYLOID B PR	RECURSOR DISORDER			
	ollowing correspondence: and Accompanying Document	s			
(Identify type of correspondence) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on February 5, 2002					
(Date)	· 	Samuel Gome (Typed or Printed Name of Person Mail			
		(Signature of Person Mailing Co EL 914 492 358 ("Express Mail" Mailing Lab	US		
	Note: Each paper must ha	eve its own certificate of mailing.	,		